Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challengeChristine M. Parseghian, Scott Kopetz, Arvind Dasari et al.|Annals of Oncology|2018Cited by 239
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim resultsChristine D. Palmer, Karin Jooss, Amy Rappaport et al.|Nature Medicine|2022Cited by 225
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid TumorsKaysia Ludford, Michael J. Overman, Won Jin Ho et al.|Journal of Clinical Oncology|2023Cited by 193
Survival improvement for patients with metastatic colorectal cancer over twenty yearsFadl A. Zeineddine, John Paul Shen, Mohammad A. Zeineddine et al.|npj Precision Oncology|2023Cited by 172
Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, <i>BRAF</i><sup>V600E</sup> metastatic colorectal cancer.Van K. Morris, Scott Kopetz, Christine M. Parseghian et al.|Journal of Clinical Oncology|2022Cited by 78